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Platelets are activated with various agonists that allow them to aggregate, thus forming either hemostatic plugs or pathologic
thrombi. Recent studies have revealed that at least two activated platelet subpopulations are formed upon potent stimulation
of platelets with collagen and/or thrombin. One of these subpopulations consists of so-called coated platelets that express
high levels of phosphatidylserine and retain a-granule proteins, including fibrinogen, on their surface. They also have reduced
levels of the main aggregation receptor-activated glycoprotein IIb-IIIa, which might indicate a defect in their proaggregatory
ability. In this study, the proaggregatory abilities of coated and noncoated platelets were assessed by means of light transmis-
sion aggregometry of suspensions with varying ratios of platelets from one subpopulation to those of a different subpopulation. A
mathematical model of platelet aggregation in heterogeneous mixtures was developed to assist in the analysis of experimental
data. Flow cytometry was employed to monitor platelet recruitment into aggregates and the ability of platelets to bind external
fibrinogen. Finally, confocal microscopy was used to image coated platelets involved into aggregates formed by mechanical
shaking. The obtained data revealed to our knowledge a novel mechanism regulating aggregate formation of platelet subpop-
ulations: coated platelets cannot aggregate with each other but can be recruited into aggregates by noncoated platelets.INTRODUCTIONBlood platelets are small (2–4 mm) anucleate cell fragments
that circulate in blood at a concentration of 2–4  105/ml.
They have a distinct property of becoming activated by a
number of physiological substances (thrombin, collagen,
ADP, thromboxane A2, etc.): this endows them with the
ability to aggregate, i.e., to form clusters. The ability to
aggregate allows them to stop bleeding by forming hemo-
static plugs and thus sustaining the integrity of the vascular
system. Under pathological conditions, this proaggregatory
ability leads to the formation of life-threatening thrombi that
are a major cause of mortality and morbidity in developed
countries.
During the last decades, all experimental and theoretical
studies of platelet aggregation assumed that activated plate-
lets are homogeneous (1). However, it was discovered that
potent stimulation of platelets with collagen and thrombin
(2,3), or with thrombin alone (4), leads to their segregation
into two subpopulations.Members of the new subpopulation,
termed coated platelets, express high levels of phosphatidyl-
serine (PS) and retain on their outer membrane surface large
amounts of several a-granule proteins, including fibrinogen,
von Willebrand factor, fibronectin, factor V, and thrombo-
spondin (3,5,6). Although there exist many studies on the
activated platelet subpopulations that do not actually use
the term coated (as recently summarized and reviewed inSubmitted February 17, 2012, and accepted for publication April 2, 2012.
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0006-3495/12/05/2261/9 $2.00Jackson andSchoenwaelder (7) andMunnixet al. (8)), forma-
tion of a distinct, highly procoagulant PS-expressing platelet
subpopulation appears to be a universal and ubiquitous
phenomenon, and this subpopulationwas often found to share
many features with coated platelets, although exceptions
were reported as well (9). Strictly speaking, platelets play
two critical roles in hemostasis and thrombosis: adhering/
aggregating at the site of vascular injury, and providing a
negatively charged surface for thrombin generation (10).
Coated and noncoated platelets are assumed to have different
procoagulant activities, since they provide vastly different
contents of PS, on which the procoagulant complexes are
assembled (11). However, it is not precisely known whether
platelets of these two subpopulations differ from each other
in their second ability, that of aggregate formation.
Three lines of evidence indicate that PS-exposing, coated
platelets probably have impaired proaggregatory ability
compared with normal activated platelets. First, they bind
10 times less PAC-1 (a monoclonal antibody that recognizes
the fibrinogen-binding site of activated glycoprotein IIb-IIIa
(GPIIbIIIa) (12), a platelet integrin required for aggregation
(13)) than noncoated platelets do, although the surface
expression of GPIIbIIIa in coated platelets is unchanged
(3,8). Second, inhibition of transglutaminase that leads to
reduction of the platelet population with coated characteris-
tics also significantly increases the rate and extent of
thrombus growth on a thrombogenic surface (14). Finally,
during thrombus formation under flow, different clusters
of platelets appear to be responsible for aggregate formationdoi: 10.1016/j.bpj.2012.04.004
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tional role in governing thrombus growth (14,15).
However, there were no attempts to investigate the
proaggregatory ability of coated platelets directly. Here,
we provide evidence from in vitro experiments that platelets
from these two distinct subpopulations, coated and non-
coated platelets, indeed have qualitatively different proag-
gregatory abilities, although the difference is more subtle
than has been expected. Coated platelets cannot bind each
other, but they efficiently participate in aggregate formation
being recruited into aggregates by noncoated platelets.MATERIALS AND METHODS
Reagents
The following materials were obtained from the sources shown in paren-
theses: convulxin (Pentapharm, Basel, Switzerland); human thrombin
(Haematologic Technologies, Essex Junction, VT); prostaglandin E1
(MP Biochemicals, Irvine, CA); R-phycoerythrin (PE)-conjugated annexin
V (Molecular Probes, Eugene, OR, or eBioscience, San Diego, CA); fluo-
rescein-5-isothiocyanate (FITC)-conjugated PAC-1 (BD Biosciences, San
Jose, CA); FITC-conjugated annexin V (BD Biosciences); PPACK (Calbio-
chem, San Diego, CA); FITC-conjugated anti-human fibrinogen antibody
(Labvision, Fremont, CA); peridinin-chlorophyll-protein (PerCP)-conju-
gated anti-human CD61 (BD Biosciences); FITC (Molecular Probes); and
Sephadex G-25 (Pharmacia, Uppsala, Sweden). Collagen-related peptide
(CRP) was kindly provided by Prof. R.W. Farndale (University of Cam-
bridge, Cambridge, UK). Glycoprotein IIb-IIIa antagonist Monafram, a
F(ab0)2 fragment of monoclonal antibody that blocks this receptor
(16,17), was a generous gift of Prof. A.V. Mazurov (Russian Cardiology
Research and Production Center, Moscow, Russia). Human fibrinogen
and all other reagents were from Sigma-Aldrich (St Louis, MO).Platelet isolation
Platelets were isolated from freshly drawn human blood of healthy volun-
teers collected with their written informed consent under approval of the
Center for Theoretical Problems of Physicochemical Pharmacology and
National Research Center for Hematology Ethical Committees essentially
as described (18). Briefly, blood was collected into 3.8% sodium citrate
with pH 5.5 at 9:1 blood/anticoagulant volume ratio and supplemented
with prostaglandin E1 (1 mM) and usually with apyrase (0.1 unit/ml) to
prevent platelet activation. It was centrifuged at 100  g for 8 min at
room temperature. The obtained platelet-rich plasma was supplemented
with 3.8% sodium citrate, pH 5.5, at 1:3 citrate/plasma volume ratio to
decrease pH. Platelets were concentrated by centrifugation at 400  g for
5 min, resuspended in buffer A (150 mM NaCl, 2.7 mM KCl, 1 mM
MgCl2, 0.4 mM NaH2PO4, 20 mM HEPES, 5 mM glucose, and 0.5%
bovine serum albumin), and subjected to gel filtration on a chromatography
column packed with Sepharose CL-2B and equilibrated with buffer A.Aggregation
Washed platelets at 100,000/ml with 2.5 mM CaCl2 in buffer A were
preincubated for 3 min at 37C and stimulated by the indicated agonists
for 15 min to allow formation of the coated and noncoated platelet subpop-
ulations (9). Then, 1 mM PPACK and 1 mg/ml fibrinogen were added, and
aggregation of the samples was monitored for 15 min by light transmission
with the Model 490 aggregometer (Chrono-log, Havertown, PA) while
stirring (800 rpm) at 37C.Biophysical Journal 102(10) 2261–2269Flow cytometry
Platelets at 100,000/ml were activated by incubation with agonists in buffer
Awith 2.5 mMCaCl2 for 15 min, additionally incubated with annexin V (2)
and appropriate antibodies (anti-fibrinogen antibody or PAC-1) for 3 min,
diluted 10-fold, and immediately analyzed in a FACSCalibur flow cytome-
ter (BD Biosciences). The acquired data were processed using WinMDI 2.8
software (Joseph Trotter, Scripps Research Institute, La Jolla, CA).Flow-cytometry-based aggregation assay
Platelets at 20,000/ml were activated by incubation with agonists in buffer A
with 2.5 mM CaCl2 for 15 min and additionally incubated with labeling
antibody and annexin V for 3 min. This was followed by addition of
1 mM PPACK and 1 mg/ml fibrinogen. Then platelets were shaken
(600 rpm) in MS1 Minishaker (IKA, Staufen, Germany) for 3 min, diluted
10-fold, and analyzed in a flow cytometer.Fibrinogen labeling
Fibrinogen (at 10 mg/ml) was dissolved in 0.1 M sodium bicarbonate
buffer, pH 9. Then, 10 mg/ml FITC dissolved in DMSO was added
(MR ¼ 5). This was followed by incubation for 2 h at 4C with continuous
stirring. The reaction was stopped by adding 1.5 M hydroxylamine, pH 8.5,
and incubation for 30 min at 4C. Then, the reaction mixture was centri-
fuged for 1 min at 16,000  g in Sephadex G-25 spin columns to separate
the conjugate from unreacted labeling reagent.Fibrinogen binding to platelet subpopulations
Platelets at 20,000/ml were activated by incubation with agonists in buffer A
with 2.5 mM CaCl2 for 15 min. Then, 1 mM PPACK was added to prevent
thrombin-induced fibrin formation. This was followed by additional incuba-
tion of platelets with annexin Vand 0.5 mg/ml FITC-conjugated fibrinogen
for 3 min. Platelets were diluted 20-fold and analyzed in a flow cytometer.Confocal microscopy
Glass coverslips (24  24 mm, Heinz Herenz, Hamburg, Germany) were
cleaned with potassium dichromate, rinsed with distilled water and dried.
The cleaned coverslips were coated with 20 mg/ml fibrinogen in buffer A
for 40 min at room temperature, rinsed with distilled water, and then
assembled as part of the flow chamber. Platelets at 20,000/ml were activated
by incubation with agonists in buffer Awith 2.5 mM CaCl2 and annexin V
for 15 min. Then, 1 mM PPACK and 1 mg/ml fibrinogen were added, and
platelets were shaken (600 rpm) in a minishaker for 3 min and allowed to
spread on the fibrinogen surface in the chamber for 20–30 min. Confocal
images of platelet aggregates were acquired with an Axio Observer.Z1
microscope (Carl Zeiss, Jena, Germany) with a 100 microscopic objec-
tive. A 488-nm laser was utilized.Statistics
All experiments were performed at least in triplicate with platelets from
different donors. Comparisons were carried out with the one-way
ANOVA test. Statistical significance was set as P < 0.05. Values are re-
ported as mean5 SE unless specified otherwise.Mathematical model of platelet aggregation
To analyze experimental data on platelet aggregation in samples containing
different subpopulations, a mathematical model was created. The principal
Aggregation of Platelet Subpopulations 2263model assumptions were: 1), platelet suspension with continuous stirring
consists of two subpopulations, one of which (the noncoated ones) aggre-
gates normally; 2), platelet aggregates grow in size as the platelets irrevers-
ibly bind each other; and 3), the probability of a collision between two
particles (either platelets or aggregates) in suspension does not significantly
depend on their size. The variables were X1, i.e., concentration of the non-
coated platelets and their aggregates, and X2, concentration of the coated
platelets and aggregates that contain them. Model equations were
dX1
dt
¼ k1  X21 ; (1)
dX2 2
dt
¼ k2  X1  X2  k3  X2; (2)
where ki are rate constants defining the stickiness of platelets. Equations 1
and 2 have the explicit solution:
X1ðtÞ ¼ 1



































X1ð0Þ  ðk1  k2Þ
; (4)where initial concentrations of platelets from distinct subpopulations are
X1(0) ¼ X10, X2(0) ¼ X20.
Light transmission, y, was assumed to be exponentially proportional to
the number of particles in suspension (20):
y ¼ Aþ B  expð  S  ðX1 þ X2ÞÞ; (5)
where S is an aggregometer-specific constant. Taking into account the
values of initial and final light transmission (y(0) ¼ 0, y(t/N) ¼ 1), we
obtained:
y ¼ 1
1 expðS  ðX1ð0Þ þ X2ð0ÞÞÞ
þ 1
1 expð  S  ðX1ð0Þ þ X2ð0ÞÞÞ
 expð  S  ðX1 þ X2ÞÞ:
(6)
A typical aggregatory curve was approximated by Hill’s equation, and
thus, ki and S in the case where all platelets in suspension aggregate equally
were determined:
k1 ¼ k3 ¼ 0.0009, k2 ¼ 0.00091, S ¼ 0.001.RESULTS
Variation of agonist concentration can be used to
obtain coated-platelet percentage up to ~90% in
suspension
To investigate proaggregatory abilities of platelets from two
distinct subpopulations, we activated platelets with agonists
of different potency. This resulted in the formation of
different percentages (up to 89.2%) of coated platelets
within 15 min (Fig. 1 A). This time interval is known to
be sufficient for coated-platelet formation to reach comple-
tion with regard to annexin V binding and downregulation
of PAC-1 binding (9) (this was also confirmed indepen-
dently by control experiments; data not shown). Indeed,
activation of platelets with thrombin alone (Fig. 1, B and
C), or dual agonist activation with thrombin plus convulxin
(not shown), resulted in segregation of activated platelets
into two distinct subpopulations. The dot plots in Fig. 1, B
and C, show that, in agreement with previous reports(3,5,8,15), PS-positive platelets have decreased PAC-1
binding (Fig. 1 B) and increased fibrinogen retention
(Fig. 1 C). These data indicate that varying the agonist
concentration can produce up to 90% of coated platelets
in suspension.Increasing coated-platelet percentage inhibits
aggregation in a nonlinear manner
To compare proaggregatory abilities of the noncoated and
coated platelets, we first compared aggregation of the
samples with different percentages of coated platelets in
the classical light transmission aggregometry assay (Fig. 2).
The speed (maximal slope of the aggregatory curve) and
extent (maximal increase of light transmission) of aggrega-
tion were estimated, as shown in Fig. 2 A. The speed of
aggregation indicated a uniform decline with the increasing
coated-platelet percentage (Fig. 2 B), whereas the extent of
aggregation remained constant in the range of ~0–60% of
coated platelets and was considerably decreased with subse-
quent increase of coated-platelet percentage (Fig. 2 C).Biophysical Journal 102(10) 2261–2269
FIGURE 1 Different agonist concentrations can produce various percent-
ages of coated platelets that have increased fibrinogen retention and
decreased PAC-1 binding. (A) Correlation of coated-platelet percentage,
determined by flow cytometry, with the degree of platelet stimulation.
Platelets (100,000/ml) were stimulated with 10, 50, or 100 nM thrombin,
50 nM thrombin plus 0.1, 0.5, 1, or 3 ng/ml convulxin, and 100 nM
thrombin plus 1, 5, 10, 100, or 1000 ng/ml convulxin (numbers 1–12 on
the x axis, consistently). Typical data obtained from the experiments with
platelets from three different donors are presented. (B and C) Dot plots
for binding of PAC-1 (B) or anti-fibrinogen antibody (C) versus annexin
V for platelets (100,000/ml) either unstimulated (left) or stimulated with
100 nM thrombin (right). The boxed area indicates the coated-platelet
subpopulation. A typical experiment out of three performed with platelets
from different donors is shown.
FIGURE 2 Inhibition of aggregation by the increasing number of coated
platelets in the sample. (A) Typical aggregation curve and its parameters,
the speed and extent of aggregation. (B and C) Dependencies of the speed
(B) and extent (C) of aggregation of platelets (100,000/ml) stimulated with
thrombin (10, 50, or 100 nM) or thrombin (50 or 100 nM) plus convulxin
(0.1, 0.5, 1, 3, 5, 50, 60, 70, 80, 90, 100, 150, 200, 500, or 1000 ng/ml)
on the percentage of coated platelets. Values are expressed as the mean5
SEM for n ¼ 2 experiments with platelets from six different donors. Solid
curves represent these dependencies based on a mathematical model for
platelets from two distinct subpopulations in the case when coated platelets
can bind noncoated ones, but fail to bind each other.
2264 Yakimenko et al.These data suggest that coated platelets somehow partici-
pate in aggregate formation; otherwise, the presence of
50% of coated platelets in suspension would significantly
inhibit both of the aggregation parameters. However, this
intuitively obvious suggestion needs to be analyzed and
proven more rigorously.Mathematical model of aggregation of platelets
from two distinct subpopulations
To interpret correctly the results from aggregometry exper-
iments, we developed a model describing interactionsBiophysical Journal 102(10) 2261–2269between platelets from two subpopulations (see Methods).
Aggregatory curves based on this model were plotted for
three cases in which 1), coated and noncoated platelets
have equal capacity to bind each other; 2), coated platelets
can bind noncoated platelets but cannot form aggregates
by themselves; and 3), coated platelets do not have the
capacity to bind any platelets. In each case, the dependen-
cies of the speed and extent of aggregation on the percentage
of coated platelets in suspension were determined (Fig. 3). If
all platelets have equal capacity to bind each other, that is,
none of the constants are zero, there is no correlation
FIGURE 3 Dependencies of aggregation parameters on the percentage of
coated platelets reflect the rate of coated-platelet participation in aggregate
formation. (A) Dependencies of light transmission on time based on the
aggregation model for platelets from two distinct subpopulations in the
case where 50% of coated platelets present in suspension. (B and C) Depen-
dencies of speed (B) and extent (C) of aggregation on the percentage of
coated platelets, based on the aggregation model for platelets from two
distinct subpopulations. The three curves on each panel represent the cases
in which 1), all platelets have equal capacity to bind each other (squares),
that is, constants are k1 ¼ k3 ¼ 0.0009, k2 ¼ 0.00091, and S ¼ 0.001; 2),
coated platelets can bind noncoated ones but fail to bind each other
(circles), that is, constants are k1 ¼ 0.0009, k2 ¼ 0.00091, k3 ¼ 0, and
S ¼ 0.001; and 3), coated platelets cannot bind any platelets (triangles),
that is, constants are k1 ¼ 0.0009, k2 ¼ k3 ¼ 0, and S ¼ 0.001.
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ters of aggregation, as shown in Fig. 3, B and C. When
coated platelets can bind noncoated platelets but fail to
bind each other, that is, k3 ¼ 0, the dependencies of aggre-
gation parameters on the percentage of coated platelets
(Fig. 3, B and C) strongly remind us of dependencies ob-
tained in our aggregometry assay. An overlay of the depen-
dencies of aggregation parameters on the percentage of
coated platelets obtained in the experimental assay and
based on the mathematical model is shown in Fig. 2, B
and C. Finally, if coated platelets fail to bind any platelets,
that is, k2 ¼ k3 ¼ 0, both aggregation parameters are drasti-
cally inhibited with the increasing number of coated plate-
lets (Fig. 3, B and C). These results point to the fact that
the data obtained in experiments using aggregometry are
caused by the participation of coated platelets together
with noncoated ones in aggregate formation. According to
this model, coated platelets cannot bind each other but are
involved into developing aggregates by noncoated platelets.
We suggest that the binding of coated and noncoated plate-
lets occurs most likely via coated platelet fibrinogen, known
to be retained on their surface of coated platelets with great
affinity (3). This may serve as a possible explanation of why
coated platelets fail to bind each other, but are good at
binding noncoated platelets.Coated platelets fail to bind external fibrinogen
As we have just seen, the data from the classical aggregom-
etry assay are in excellent agreement with the model
wherein coated platelets cannot aggregate with each other
but can be recruited into aggregates by noncoated platelets.
To examine directly whether coated platelets indeed
have impaired capacity for binding external fibrinogen in
addition to that retained on their surface, flow cytometric
studies were performed. Activated platelet binding of
FITC-conjugated fibrinogen was estimated (Fig. 4). TheFIGURE 4 Coated platelets fail to bind external fibrinogen. (A and B)
Dot plots for binding of fibrinogen-FITC versus annexin V for platelets
(20,000/ml) either unstimulated (A) or stimulated with 200 nM thrombin
(B). The boxed area indicates the coated-platelet subpopulation. Shown is
a typical experiment out of three performed with platelets from different
donors.
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2266 Yakimenko et al.mean fluorescence intensity of noncoated platelets was
91.4 5 17.8 a.u., whereas those of coated and untreated
platelets were 8 5 0.4 and 3.6 5 0.1 a.u. (n ¼ 3), respec-
tively. That is, only noncoated platelets readily bound
external fibrinogen, whereas coated platelets almost
completely failed to do so.Coated platelets participate in aggregate
formation by being recruited into aggregates
by noncoated platelets
To test the second part of our hypothesis, that coated plate-
lets participate in aggregate formation because they are re-
cruited into developing aggregates by noncoated platelets,
other flow cytometric studies were performed. Platelets
were activated so, that there were both coated and noncoated
platelets, allowed to form aggregates by shaking for several
minutes, and analyzed by flow cytometer. Numbers of
coated and noncoated platelets excluding aggregates for
samples with and without the shaking were compared
(Fig. 5). Percentages of noncoated and coated platelets
leaving the suspension after shaking to form aggregates
were 68.6 5 7.4% (n ¼ 3, P < 0.05) and 26.1 5 5.3%
(n ¼ 3, P < 0.05), respectively.
Participation of coated platelets in aggregate formation is
most likely due to fibrinogen retention on the coated-platelet
surface. The unoccupied terminus of a coated-platelet fibrin-
ogen molecule interacts with an activated GPIIbIIIa receptor
on the adjacent noncoated platelet, and thus the aggregationBiophysical Journal 102(10) 2261–2269occurs. The assumption that aggregate formation in this
experimental model is dependent on GPIIbIIIa was tested
by using a GPIIbIIIa antagonist Monafram. The presence
of excess Monafram during platelet activation prevented
the platelets from leaving the suspension, and almost no
aggregates were observed (data not shown). These results
support the hypothesis that noncoated platelets act like
bridges between coated ones in the developing aggregates.
The difference in the involvement of the two platelet
subpopulations into the aggregates may vary quantitatively
with the amount of fibrinogen added. Given our suggestion
that coated platelets are recruited into developing aggre-
gates via the fibrinogen retained on their surface, the addi-
tion of external fibrinogen may cause competition between
the coated platelets and the added fibrinogen molecules
for fibrinogen binding sites on noncoated platelets. A fibrin-
ogen concentration of 1 mg/ml was chosen as comparable to
its plasma concentration and was added in the experiments
throughout this study to compare correctly the results ob-
tained from different assays.Confocal microscopy reveals coated platelets
involved into the aggregates
To confirm the flow cytometric results, showing that partic-
ipation of coated platelets in the aggregates does take place,
the annexin-V-labeled aggregates formed upon conditions
used in our cytometric studies were imaged by confocal
microscopy. Fig. 6 demonstrates the typical look ofFIGURE 5 Coated platelets participate in aggre-
gate formation being recruited into aggregates by
noncoated platelets. (A–C) Dot plots for binding
of CD61 (upper), contour plots (middle), and dot
plots for binding of annexin V (lower) for platelets
(20,000/ml) either unstimulated (A) or stimulated
with 50 nM thrombin and 50 ng/ml convulxin
without (B) and with (C) shaking. Events showing
a high level of CD61 binding are marked as region
R5 for unactivated platelets (A) and region R1 for
activated platelets (B and C). R2 is the region of
activated individual platelets and R3 the region
of aggregates. Shown is a typical experiment out
of three performed with platelets from different
donors.
FIGURE 6 Coated platelets are incorporated into the aggregates formed
by shaking. Representative confocal images of DIC, FITC (green) fluores-
cence of annexin V, and an overlay of the two for an aggregate of platelets
stimulated with 100 nM thrombin plus 5 mg/ml CRP are shown. All panels
represent one field of view. Two optical cross sections of an aggregate sepa-
rated by 4.6 mm (A and B) are shown. Note that round-shaped annexin-V-
positive platelets are held together by annexin-V-negative platelets with
altered structure. Scale bar, 5 mm.
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are held together by mushy structures of PS-negative plate-
lets, in agreement with the concept that coated platelets can
aggregate with noncoated ones but not with each other.DISCUSSION
This study aimed to investigate the proaggregatory abilities
of two platelet subpopulations produced upon stimulation of
platelets with thrombin or thrombin plus glycoprotein VI
agonist. The principal finding is that highly procoagulant
fibrinogen-coated platelets cannot bind each other but can
be recruited into aggregates by noncoated platelets.
Four lines of evidence support this conclusion: 1), partial
inhibition of platelet aggregation by coated platelets in the
conventional aggregometry assay; 2), impaired ability of
coated platelets to bind external fibrinogen; 3), demonstra-
tion by flow cytometry that coated platelets can be recruited
into aggregates; 4), direct confocal microscopic visualiza-
tion of coated platelets in the aggregates formed by shaking.
Up to 90% of coated-platelet content in suspension was
achieved upon potent platelet stimulation with thrombin or
thrombin plus convulxin by varying agonist concentrations.
A large percentage (60% or more) of coated platelets in-
hibited aggregation in the sample, whereas the presence of
50% of coated platelets did not change the extent of aggre-
gation, suggesting that coated platelets somehow participate
in aggregate formation, albeit to a lesser degree. Theoreti-
cally, the differences in proaggregatory ability of suspen-
sions with platelets from two distinct subpopulations may
result not only from the different percentages of coatedplatelets in them, but also from some abnormalities, which
platelets might have due to the stimulation of different
potency. However, this possibility seems to be negligible,
because flow cytometry revealed neither significant differ-
ences in platelets activated by a range of agonist concentra-
tions nor signs of their desensitization.
The suggestion that coated platelets participate in aggre-
gate formation was strongly confirmed by results obtained
from the mathematical model of aggregation describing
interactions between platelets from two subpopulations in
three possible cases, in which 1), coated and noncoated
platelets have equal capacity to bind each other; 2), coated
platelets can bind noncoated ones but cannot form aggre-
gates by themselves; and 3), coated platelets do not have
the capacity to bind any platelets. When all platelets had
equal capacity to bind each other, there was no correlation
between the percentage of coated platelets and the parame-
ters of aggregation. When coated platelets could bind
noncoated ones but failed to bind each other, the dependen-
cies of aggregation parameters on the percentage of coated
platelets strongly reminded us of dependencies obtained in
our aggregometry assay. Finally, when coated platelets
failed to bind any platelets, the speed and extent of aggrega-
tion were drastically inhibited with the increasing number of
coated platelets. These results point to the fact that the data
obtained in experiments using aggregometry were caused by
the participation of coated platelets in aggregate formation
together with noncoated ones. According to this model,
coated platelets cannot bind each other but are recruited into
developing aggregates by noncoated platelets. A serious
assumption was made that the probability of a collision
between two particles does not depend on their size.However,
the relevancy of using this simplified model arises from the
fact that formation of large aggregates containing >10–20
platelets is considered to be quite slow. This means that by
the time large aggregates,whose size can in nowaybe equated
to the size of an individual platelet, were formed, measure-
ments of light transmission had already been completed.
Second, only noncoated platelets had the capacity to bind
external fibrinogen from a suspension, which molecules are
known to serve as bridges between two adjacent platelets or
between a platelet and the thrombogenic surface in aggrega-
tion or adhesion (21,22), while coated platelets failed to
bind it.
Furthermore, flow cytometry revealed that coated plate-
lets readily leave the suspension to form aggregates together
with noncoated ones. The main drawback of this approach is
similar to that of the aggregometry assay, consisting in the
theoretically possible defects, which platelets might have
due to the intensive shaking. These defects themselves
may be the cause of coated platelets leaving the suspension,
and not necessarily to form aggregates only. Finally, coated
platelets in aggregates were detected by confocal micros-
copy, indicating their participation in aggregate formation
provoked by shaking.Biophysical Journal 102(10) 2261–2269
FIGURE 7 Coated platelets do not aggregate with each other but are re-
cruited into aggregates by noncoated platelets: a possible mechanism.
Capacities of platelets from two distinct subpopulations for binding each
other are illustrated. Irregular shapes (A and B) depict normal activated
platelets. Round shapes (B and C) depict coated platelets. Colored mole-
cules on the coated-platelet surface represent receptors and their ligands,
which form the coat of the coated platelet. (A) The interaction between
two noncoated platelets occurs via fibrinogen (red) binding with GPIIbIIIa
receptors (black). (B) Interaction between coated and noncoated platelets
occurs when a GPIIbIIIa receptor on the noncoated platelet surface binds
the free terminus of a fibrinogen molecule retained on the coated-platelet
surface. (C) The interaction between two coated platelets cannot occur,
since they have no active or free GPIIbIIIa receptors capable of binding
the fibrinogen retained on the coated-platelet surface. The curve between
platelets symbolizes the impossibility of their forming an aggregate by
interaction with each other.
2268 Yakimenko et al.All these experiments were performed after 15 min of
incubation with the agonists, when both platelet subpopula-
tions, coated and noncoated platelets, had already formed. It
makes our studies suitable for processes in hemostasis at
low shear rates, where the aggregation mechanism primarily
requires platelet activation (23–25). However, additional
in vivo experiments and studies in flow chambers at
different shear velocities will be needed to finalize the
mechanism of coated-platelet participation in aggregate
formation. Another problem, not addressed in this study,
is how the increased procoagulant function of coated-
platelet aggregates may affect thrombus dynamics and
whether such aggregates lead to increased thrombin gener-
ation followed by fibrin formation and stabilization or prop-
agation of thrombi.
Although PS-expressing platelets formed upon potent
stimulation of platelets with thrombin or thrombin plus con-
vulxin are known to have decreased PAC-1 binding, there
has been no previous direct evidence on whether they can
or cannot successfully participate in aggregate formation.
It has been shown that during thrombus formation under
flow, annexin-V-positive platelets assemble around the clots
composed of annexin-V-negative PAC-1-binding platelets
(9), which is actually very much in line with the coated-
platelet aggregation mechanism revealed in this study.
However, since those experiments were performed in whole
blood in the presence of coagulation, it was not feasible to
reliably deduce the specific mechanisms from those obser-
vations in a complex system.We suggest that coated-platelet
participation in aggregate formation is provided mostly by
the fibrinogen known to be retained on the surface of
these platelets with an exceptional affinity (5), though von
Willebrand factor may also play a role. It is noteworthy
that formaldehyde-fixed platelets bearing cross-linked
fibrinogen and erythrocytes with covalently bound fibrin-
ogen were reported to participate in aggregate formation
in the same manner as do coated platelets in the experiments
of our study. These platelet substitutes do not aggregate by
themselves but are incorporated into aggregates of activated
platelets (26,27).
The mechanism of aggregation of platelets from two
distinct subpopulations based on the data of this study is
presented in Fig. 7. Briefly, coated platelets cannot bind
each other but do bind noncoated platelets. Basic observa-
tions regarding coated platelets that are reproduced in our
scheme include the following: coated platelets retain on
their surface large amounts of procoagulant proteins;
fibrinogen is bound to coated platelets with excep-
tional affinity (28); and GPIIbIIIa receptors on coated
platelets are inactive or occupied with some ligand (3)
(not shown).
The most intriguing question in the platelet heterogeneity
field is the physiological roles of the two platelet subpopu-
lations. Reduced PAC-1 binding of coated platelets and the
possibility of having a reduced proaggregatory ability led toBiophysical Journal 102(10) 2261–2269suggestions that annexin-V-positive, or coated, platelets can
participate in the downregulation of thrombus growth
(14,15). On the other hand, coated platelets are known to
sustain a procoagulant response by accelerating thrombin
production by providing the PS necessary for membrane-
dependent reactions catalyzed by tenase and prothrombi-
nase complexes (29). Therefore, it was not clear how they
could carry out their procoagulant function unless they
have a way of incorporating into a thrombus. The data of
this study suggest that they do possess such a way, via
contacts with noncoated platelets, to get into a thrombus
and there carry out their procoagulant function. Actually,
one might speculate that this function itself could contribute
to the downregulation of further platelet attachment by pro-
viding a fibrin surface with low adhesive properties (30).
This seems to be a more probable mechanism than their
direct anti-aggregatory properties for stopping thrombus
growth, considering the significant time required to produce
coated platelets, their ability to aggregate rather well with
noncoated ones, and the very high percentage of coated
platelets required to inhibit aggregation observed in our
study. However, it is quite probable that the inability of
strongly activated platelets to aggregate with each other is
an additional physiological protective mechanism against
thrombosis.
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